Novadip Biosciences Raises Additional Eur 40 Million Bringing Total Company Funding To Eur 88 Million
Amount Raised
€40 Million
Round Type
Funding Round
BelgiumBiotechnologyHealth CareMedicalTherapeuticsDescription
Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, today announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding. The funding will accelerate the clinical development of two of Novadip’s investigational adipose stem cell (ASC)-derived tissue regeneration products: NVD-X3, an allogeneic therapeutic that can provide accelerated, durable bone union in spinal fusion procedures and non-healing fractures, and NVD-003, an autologous bone engraftment product designed to provide a single treatment cure for patients with critical size bone defects such as congenital pseudoarthrosis of the tibia (CPT).
Who to call at Novadip Biosciences, and when
A new round usually means Novadip Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Novadip Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novadip Biosciences, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novadip Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Novadip Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.